Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Long-term benefits of omalizumab in a patient with severe non-allergic asthma. | Menzella et al. Allergy Asthma Clinical Immunology 2011 7 9 http content 7 1 9 ALLERGY ASTHMA CLINICAL IMMUNOLOGY CASE REPORT Open Access Long-term benefits of omalizumab in a patient with severe non-allergic asthma Francesco Menzella Roberto Piro Nicola Facciolongo Claudia Castagnetti Anna Simonazzi and Luigi Zucchi Abstract Introduction Currently omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy. Case presentation We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab he presented a significant improvement in disease control in terms of hospitalizations exacerbation quality of life and lung function with good safety profile. Conclusion Our case shows after a long follow-up how omalizumab can be effective in a severe form of nonatopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic. Introduction Patients with severe asthma often have a poor control of their disease they represent the subgroup that absorbs most of the costs 1 2 for these reasons it has given rise to the need to get new drugs able to improve control. The only biological drug available for the treatment of severe asthma is omalizumab. A number of clinical trials have been performed in order to evaluate either the efficacy or the safety of the above-mentioned drug the results showed that this molecule is able to significantly improve asthma control and quality of life with an excellent safety profile 3-5 . Actually as set by the European Medicine Agency EMA 6 and GINA Guidelines 7 in Europe omalizu-mab is indicated as an add-on therapy aimed at improving asthma control in adult and adolescent .
